{"id":20950,"date":"2022-01-13T05:12:00","date_gmt":"2022-01-12T21:12:00","guid":{"rendered":"http:\/\/csccm.org.cn\/?p=20950"},"modified":"2022-01-13T07:03:52","modified_gmt":"2022-01-12T23:03:52","slug":"lancet%e5%8f%91%e8%a1%a8%e8%ae%ba%e6%96%87%ef%bc%9amrna%ef%bc%8c%e7%97%85%e6%af%92%e8%bd%bd%e4%bd%93%e4%b8%8e%e8%9b%8b%e7%99%bd%e4%bd%90%e5%89%82%e7%ad%89%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92","status":"publish","type":"post","link":"https:\/\/csccm.org.cn\/?p=20950","title":{"rendered":"[Lancet\u53d1\u8868\u8bba\u6587]\uff1amRNA\uff0c\u75c5\u6bd2\u8f7d\u4f53\u4e0e\u86cb\u767d\u4f50\u5242\u7b49\u65b0\u51a0\u75c5\u6bd2\u75ab\u82d7\u6df7\u5408\u63a5\u79cd\u7684\u514d\u75ab\u539f\u6027\u3001\u5b89\u5168\u6027\u4e0e\u53cd\u5e94\u539f\u6027"},"content":{"rendered":"\n

ARTICLES|ONLINE FIRST<\/a><\/p>\n\n\n\n

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial<\/h1>\n\n\n\n

Arabella S V Stuart, Robert H Shaw, Xinxue Liu,\u00a0et al<\/h3>\n\n\n\n

Lancet Published:December 06, 2021<\/h3>\n\n\n\n

DOI:https:\/\/doi.org\/10.1016\/S0140-6736(21)02718-5<\/a><\/h3>\n\n\n\n

Summary<\/h2>\n\n\n\n

Background<\/h3>\n\n\n\n

Given the importance of flexible use of different COVID-19 vaccines within the same schedule to facilitate rapid deployment, we studied mixed priming schedules incorporating an adenoviral-vectored vaccine (ChAdOx1 nCoV-19 [ChAd], AstraZeneca), two mRNA vaccines (BNT162b2 [BNT], Pfizer\u2013BioNTech, and mRNA-1273 [m1273], Moderna) and a nanoparticle vaccine containing SARS-CoV-2 spike glycoprotein and Matrix-M adjuvant (NVX-CoV2373 [NVX], Novavax).<\/p>\n\n\n\n

Methods<\/h3>\n\n\n\n

Com-COV2 is a single-blind, randomised, non-inferiority trial in which adults aged 50 years and older, previously immunised with a single dose of ChAd or BNT in the community, were randomly assigned (in random blocks of three and six) within these cohorts in a 1:1:1 ratio to receive a second dose intramuscularly (8\u201312 weeks after the first dose) with the homologous vaccine, m1273, or NVX. The primary endpoint was the geometric mean ratio (GMR) of serum SARS-CoV-2 anti-spike IgG concentrations measured by ELISA in heterologous versus homologous schedules at 28 days after the second dose, with a non-inferiority criterion of the GMR above 0\u00b763 for the one-sided 98\u00b775% CI. The primary analysis was on the per-protocol population, who were seronegative at baseline. Safety analyses were done for all participants who received a dose of study vaccine. The trial is registered with ISRCTN, number 27841311.<\/p>\n\n\n\n

Findings<\/h3>\n\n\n\n

Between April 19 and May 14, 2021, 1072 participants were enrolled at a median of 9\u00b74 weeks after receipt of a single dose of ChAd (n=540, 47% female) or BNT (n=532, 40% female). In ChAd-primed participants, geometric mean concentration (GMC) 28 days after a boost of SARS-CoV-2 anti-spike IgG in recipients of ChAd\/m1273 (20\u2009114 ELISA laboratory units [ELU]\/mL [95% CI 18\u2009160 to 22\u2009279]) and ChAd\/NVX (5597 ELU\/mL [4756 to 6586]) was non-inferior to that of ChAd\/ChAd recipients (1971 ELU\/mL [1718 to 2262]) with a GMR of 10\u00b72 (one-sided 98\u00b775% CI 8\u00b74 to \u221e) for ChAd\/m1273 and 2\u00b78 (2\u00b72 to \u221e) for ChAd\/NVX, compared with ChAd\/ChAd. In BNT-primed participants, non-inferiority was shown for BNT\/m1273 (GMC 22\u2009978 ELU\/mL [95% CI 20\u2009597 to 25\u2009636]) but not for BNT\/NVX (8874 ELU\/mL [7391 to 10\u2009654]), compared with BNT\/BNT (16\u2009929 ELU\/mL [15\u2009025 to 19\u2009075]) with a GMR of 1\u00b73 (one-sided 98\u00b775% CI 1\u00b71 to \u221e) for BNT\/m1273 and 0\u00b75 (0\u00b74 to \u221e) for BNT\/NVX, compared with BNT\/BNT; however, NVX still induced an 18-fold rise in GMC 28 days after vaccination. There were 15 serious adverse events, none considered related to immunisation.<\/p>\n\n\n\n

\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n

Interpretation<\/h3>\n\n\n\n

Heterologous second dosing with m1273, but not NVX, increased transient systemic reactogenicity compared with homologous schedules. Multiple vaccines are appropriate to complete primary immunisation following priming with BNT or ChAd, facilitating rapid vaccine deployment globally and supporting recognition of such schedules for vaccine certification.<\/p>\n\n\n\n

Funding<\/h3>\n\n\n\n

UK Vaccine Task Force, Coalition for Epidemic Preparedness Innovations (CEPI), and National Institute for Health Research. NVX vaccine was supplied for use in the trial by Novavax.<\/p>\n","protected":false},"excerpt":{"rendered":"

ARTICLES|ONLINE FIRST Immunogenicity, safety, and react […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[32,23],"tags":[],"_links":{"self":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/20950"}],"collection":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20950"}],"version-history":[{"count":2,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/20950\/revisions"}],"predecessor-version":[{"id":21057,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/20950\/revisions\/21057"}],"wp:attachment":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20950"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20950"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20950"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}